Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:CHRS

Coherus Oncology Q3 2026 Earnings Date & Estimates

Coherus Oncology logo
$1.07 +0.06 (+5.94%)
Closing price 10/27/2026 04:00 PM Eastern
Extended Trading
$1.06 -0.02 (-1.40%)
As of 10/27/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Coherus Oncology is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Coherus Oncology in Q3 2026

Coherus Oncology is expected to post earnings of -$0.21 per share on revenue of $15.98 million. In the same quarter a year earlier Coherus Oncology reported -$0.33 per share on revenue of $11.57 million. Coherus Oncology last reported on August 5, 2026, posting -$0.19 per share and beating the -$0.25 consensus estimate. Coherus Oncology has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.21
Expected Revenue
$15.98 million
Prior-Year EPS
-$0.33
Prior-Year Revenue
$11.57 million
Expected Revenue Growth
+38.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.19 (Beat by +$0.06)
Last Quarter Revenue
$14.31 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Coherus Oncology Q3 2026 Earnings FAQ

Coherus Oncology (NASDAQ:CHRS) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Coherus Oncology's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Coherus Oncology to post earnings of -$0.21 per share for Q3 2026.

The consensus revenue estimate for Coherus Oncology is $15.98 million for Q3 2026.

Coherus Oncology Earnings Headlines

Coherus to Participate in Upcoming Investor Conferences
October 27 at 9:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3389149/33333/en/coherus-to-participate-in-upcoming-investor-conferences.html
Coherus Oncology Announces Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for November 9
October 26 at 9:51 AM  |  quiverquant.comQ
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
 |  Crypto 101 Media (Ad)
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
October 26 at 9:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/26/3388192/33333/en/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026.html
Coherus Oncology to Release Interim Clinical Data From Tagmokitug Program on October 28
October 14, 2026  |  quiverquant.comQ
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3381161/33333/en/coherus-oncology-to-host-webcast-to-disclose-interim-tagmokitug-clinical-data-on-october-28-2026.html
See More Coherus Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coherus Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coherus Oncology and other key companies, straight to your email.

About Coherus Oncology

Coherus Oncology (NASDAQ:CHRS), formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma. Coherus has also developed biosimilar products in areas such as immunology and ophthalmology, including YUSIMRY, a biosimilar to Humira, and CIMERLI, a biosimilar to Lucentis.

Coherus was founded in 2010 and has historically focused on expanding the availability of biologic medicines through internal development, regulatory approvals and commercial partnerships. The company serves the U.S. market and has collaborated with international partners, including China-based Junshi Biosciences, to develop and commercialize selected products. Coherus has been led by co-founder and Chief Executive Officer Denny Lanfear.

View Coherus Oncology Profile
Earnings Tools